FINWIRES · TerminalLIVE
FINWIRES

米イラン和平協議への期待感からニュージーランド株が上昇。コーラス社は第3四半期の光ファイバー接続数が110万件に達したと発表。

-- ニュージーランド株は水曜日、米イラン和平協議の継続への期待感からアジア市場の大半が上昇したことを受け、上昇して取引を終えた。 S&P/NZX 50指数は0.46%(59.32ポイント)上昇し、13,076.58で引けた。 ロイター通信が火曜日に報じたところによると、ドナルド・トランプ米大統領は火曜日、米イラン戦争終結に向けた和平協議が今後2日間でパキスタンで再開される可能性があると述べた。 ロイター通信が別の記事で引用したIG証券のアナリスト、トニー・シカモア氏は、「リスク資産の目覚ましい値動きは、市場が中東紛争の直接的な影響を先読みしようとしていることを示唆している」と述べた。 国内ニュースでは、取引プラットフォームのデータによると、火曜日に開催されたグローバル・デイリー・トレード(GDT)の豆類オークションで、合計2,869トン(MT)の製品が落札され、供給量は2,550MTから3,000MTの範囲だった。企業ニュースでは、コーラス(ASX:CNU)が、第3四半期の光ファイバー接続数が13,000件増加し、110万件に達したと発表しました。これは、第2四半期の7,000件増を上回る伸びです。 ライマン・ヘルスケア(ASX:RYM、NZE:RYM)は、第4四半期の占有権契約(ORA)販売件数が331件となり、前年同期の302件から10%増加したと発表しました。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB